mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Chugai witnesses sales growth in 2009

Posted on 04/02/2010 in Pharmaceutical Company Financials

Chugai's financial results for 2009 have been reported by Roche, which owns the majority stake in the organisation.

Last year, the pharmaceutical company witnessed an increase in sales, driven largely by demand for the H1N1 virus product Tamiflu, Roche stated.

This growth was also attributed to the popularity of Chugai's key cancer medicines and Actemra (tocilizumab) - the first humanised interleukin-6 receptor-inhibiting monoclonal antibody for the treatment of rheumatoid arthritis.

Additionally, Chugai recorded significant additional growth in the fourth quarter, following the approval of an expanded metastatic colorectal cancer indication.

Severin Schwan, chief executive of Roche, stated: "In a turbulent external environment, Roche performed extraordinarily well. Sales by both pharma and diagnostics grew twice as fast as their respective markets."

As of the end of December 2009, Roche owns 59.9 per cent of Chugai's outstanding shares, equating to 61.6 per cent of its voting rights.

In December, Chugai announced that management restructures have taken place as a result of its new ownership.

Other news stories from 04/02/2010

Read more in the Zenopa News Archive

How this news is generated

Jo-Anne
Account Manager
for this opportunity

01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com

Latest News

Chugai receives backing for new RoActemra indication

Chugai reveals internal restructuring

Chugai witnesses sales growth in 2009

Chugai announces changes to its management structure

Chugai and BioComber reach patent agreement for PURESYSTEM

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use